Skip to Content
Merck

C-053

Carbamazepine solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Slide 1 of 1
Sign In to View Organizational & Contract Pricing.

Select a Size

1 ML

355,00 kr

355,00 kr

Please contact Customer Service for Availability
Request a Bulk Order

About This Item

Empirical Formula (Hill Notation):
C15H12N2O
CAS Number:
298-46-4
Molecular Weight:
236.27
UNSPSC Code:
41116107
NACRES:
NA.24
MDL number:
MFCD00005073

Key Documents

View All Documentation

Skip To

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Carbamazepine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

InChI

1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)

SMILES string

O=C(N)N1C2=C(C=CC=C2)C=CC3=C1C=CC=C3

InChI key

FFGPTBGBLSHEPO-UHFFFAOYSA-N

grade

certified reference material

form

liquid

feature

SNAP-N-SPIKE®, SNAP-N-SHOOT®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

Quality Level

300

Gene Information

human ... SCN10A(6336), SCN11A(11280), SCN1A(6323), SCN2A(6326), SCN3A(6328), SCN4A(6329), SCN5A(6331), SCN7A(6332), SCN8A(6334), SCN9A(6335)

Related Categories

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
PHR10671093001C0450000
Carbamazepine solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

C-053

Carbamazepine solution

Carbamazepine Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1067

Carbamazepine

Carbamazepine United States Pharmacopeia (USP) Reference Standard

USP

1093001

Carbamazepine

Carbamazepine European Pharmacopoeia (EP) Reference Standard

C0450000

Carbamazepine

technique(s)

gas chromatography (GC): suitable, liquid chromatography (LC): suitable

technique(s)

HPLC: suitable, gas chromatography (GC): suitable

technique(s)

-

technique(s)

-

format

single component solution

format

neat

format

neat

format

neat

form

liquid

form

-

form

-

form

-

Quality Level

300

Quality Level

300

Quality Level

-

Quality Level

-

grade

certified reference material

grade

certified reference material, pharmaceutical secondary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

storage temp.

−20°C

storage temp.

2-30°C

storage temp.

-

storage temp.

2-8°C

General description

Carbamazepine is an anticonvulsant and mood stabilizing drug used primarily in the treatment of epilepsy and neuropathic pain. Marketed under trade names including Carbatrol®, Tegretol®, Carbamaze, and Biston, carbamazepine is also used as a second line treatment for bipolar disorder and in conjunction with antipsychotic drugs for schizophrenia. Suitable uses of this Certified Spiking Solution® include as starting material for preparation of calibrators and controls in carbamazepine testing methods by GC/MS or LC/MS for clinical toxicology, pain prescription monitoring, forensic analysis, or therapeutic drug monitoring applications.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Carbatrol is a registered trademark of Pharmavene, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Tegretol is a registered trademark of Novartis Corporation

target_organs

Eyes

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - Skin Sens. 1 - STOT SE 1

Storage Class

3 - Flammable liquids

wgk

WGK 1

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Inge Anita Meijer et al.
Muscle & nerve, 49(1), 134-138 (2013-07-31)
Erythromelalgia due to heterozygous gain-of-function SCN9A mutations usually presents as a pure sensory-autonomic disorder characterized by recurrent episodes of burning pain and redness of the extremities. We describe a patient with an unusual phenotypic presentation of gross motor delay, childhood-onset
Emilie Caietta et al.
Pediatrics, 132(3), e784-e787 (2013-08-21)
Mutations of SCN4A encoding the skeletal muscle sodium channel Nav 1.4 cause several types of disease, including sodium channel myotonias. The latter may be responsible for neonatal symptoms, including severe neonatal episodic laryngospasm (SNEL). Establishing the diagnosis of SCN4A-related SNEL
V L Yip et al.
Clinical pharmacology and therapeutics, 92(6), 757-765 (2012-11-08)
Carbamazepine (CBZ) therapy is associated with cutaneous adverse reactions in up to 10% of patients. Predisposition to these hypersensitivity reactions has been linked to the human leukocyte antigen (HLA) genotype. This systematic review determines the strength of these associations and
Janneke Jentink et al.
BMJ (Clinical research ed.), 341, c6581-c6581 (2010-12-04)
To identify specific major congenital malformations associated with use of carbamazepine in the first trimester of pregnancy. A review of all published cohort studies to identify key indications and a population based case-control study to test these indications. Review of
U Amstutz et al.
Clinical pharmacology and therapeutics, 94(1), 142-149 (2013-04-17)
The occurrence of hypersensitivity reactions including rare but life-threatening Stevens-Johnson syndrome (SJS) and drug-induced hypersensitivity syndrome (HSS) limits the use of the anticonvulsant carbamazepine (CBZ). Human leukocyte antigen-B (HLA)-B 15:02 and HLA-A 31:01 have been identified as predictive genetic markers
View All Related Papers

Articles

Protein Binding Determination - Comparison Study of Techniques & Devices

Comparative analysis of Supel™ BioSPME 96-Pin device with a rapid equilibrium dialysis technique for accuracy of measured values, sample cleanliness, and workflow time in drug protein binding.

Speed, Simplicity and Accuracy of Protein Binding Determination using BioSPME

Learn about Supel™ BioSPME C18 high-throughput devices to determine plasma protein binding and decrease the sample preparation time to less than an hour.

Protein Binding Determination Using Supel™ BioSPME C18 Pin Device as Part of the Manual Methodology With and Without Shaking

The application note describes a comparative analysis of plasma protein binding results for free/bound drugs using two different sample extraction steps, with and without agitation.

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service